article thumbnail

Drug developers look at innovative mechanisms to tackle dry eye syndrome

Pharmaceutical Technology

Dry eye syndrome (DES) is an indication whose mainstay treatment has been dominated by Allergan’s Restasis (cyclosporine ophthalmic emulsion 0.05%) ever since its launch in 2003 in the US. Current treatment options for DES are dominated by a mix of prescription and over-the-counter (OTC) products.

article thumbnail

The Inflation Reduction Act Passed, Now What?

PM360

In April 2022, we released an article describing proposed policies from the federal government that could impact prescription drug pricing. Patient behavior on insulin: Part D plans will have limited opportunity to adjust strategy for 2023, given bids are locked in. The IRA affects several components of the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A Primer on Telepharmacy

Nixon Gwilt Law

And that’s because pharmacy is an incredibly important part of the healthcare ecosystem—for many patients, they see their pharmacist far more often than their primary care physician. Due to the success of the North Dakota Telepharmacy Project, the Board of Pharmacy in North Dakota permanently implemented telepharmacy regulations in 2003.

Medical 52
article thumbnail

Beating the Big C

Pharmaceutical Technology

It has boosted anti-tumour research by 60% since 2005, at a cost of $1.6bn, in the hope of increasing the share of company sales attributed to cancer drugs from the current level of 5% “There are a lot of patients that are suffering,” said Pfizer chief executive Jeffrey Kindler.